MDWD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.88M

+34.91%

-0.594

+65%

6.28M

+58.7%

-0.597

+752.39%

6.77M

+18.66%

-0.580

-52.85%

Estimates Revision

The market is revising No Change the revenue expectations for MediWound Ltd. (MDWD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.50%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+9.50%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

30.00

High

36.00

Current: 0.000

Low

25.00

Averages

30.00

High

36.00

H.C. Wainwright

Buy

maintain

$31 -> $36

2025-11-21

Reason

H.C. Wainwright

Price Target

$31 -> $36

2025-11-21

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on MediWound to $36 from $31 and keeps a Buy rating on the shares. The company's new manufacturing facility with six-fold increased capacity is on track to begin commercial production in mid-2026, the analyst tells investors in a research note.

Oppenheimer

Outperform

downgrade

$36 -> $34

2025-06-02

Reason

Oppenheimer

Price Target

$36 -> $34

2025-06-02

downgrade

Outperform

Reason

Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.

H.C. Wainwright

Swayampakula Ramakanth

Buy

upgrade

$25 -> $31

2025-05-22

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

$25 -> $31

2025-05-22

upgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on MediWound to $31 from $25 and keeps a Buy rating on the shares following the Q1 report.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$25

2025-03-20

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$25

2025-03-20

Reiterates

Strong Buy

Reason

Craig-Hallum

Chase Knickerbocker

Strong Buy

Initiates

$39

2025-02-28

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$39

2025-02-28

Initiates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$25

2025-01-10

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$25

2025-01-10

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Mediwound Ltd (MDWD.O) is -7.84, compared to its 5-year average forward P/E of -8.05. For a more detailed relative valuation and DCF analysis to assess Mediwound Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.05

Current PE

-7.84

Overvalued PE

-5.33

Undervalued PE

-10.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.22

Current EV/EBITDA

-6.96

Overvalued EV/EBITDA

1.41

Undervalued EV/EBITDA

-11.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.36

Current PS

8.33

Overvalued PS

7.32

Undervalued PS

3.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MDWD News & Events

Events Timeline

No data

News

9.0

2025-12-10Globenewswire

MediWound Reports NexoBrid Reduces Traumatic Tattoo Risk by 92.5%

9.0

2025-12-10Newsfilter

MediWound Reports NexoBrid's 92.5% Effectiveness in Preventing Traumatic Tattoos

6.0

2025-11-21Benzinga

Palo Alto Set to Surge by 30%? Check Out 10 Leading Analyst Predictions for Friday

People Also Watch

Frequently Asked Questions

What is Mediwound Ltd (MDWD) stock price today?

The current price of MDWD is 19.3 USD — it has decreased -0.36 % in the last trading day.

What is Mediwound Ltd (MDWD)'s business?

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

What is the price predicton of MDWD Stock?

What is Mediwound Ltd (MDWD)'s revenue for the last quarter?

Mediwound Ltd revenue for the last quarter amounts to 5.43M USD, increased 24.66 % YoY.

What is Mediwound Ltd (MDWD)'s earnings per share (EPS) for the last quarter?

Mediwound Ltd. EPS for the last quarter amounts to -0.24 USD, decreased -75.51 % YoY.

What changes have occurred in the market's expectations for Mediwound Ltd (MDWD)'s fundamentals?

How many employees does Mediwound Ltd (MDWD). have?

Mediwound Ltd (MDWD) has 111 emplpoyees as of January 09 2026.

What is Mediwound Ltd (MDWD) market cap?

Today MDWD has the market capitalization of 248.35M USD.